SITE Centers Corp. SITC
0.68 USD 0.00 (-0.37%)
At closeNov 11, 2026, 4:00 PM EST
0.70 +0.02 +3.26%
After hours · Nov 11, 4:00 PM ET
0.6504 Day range 0.694
0.59 52-week range 7.49
- YTD
- -89.45%
- 1 year
- -90.67%
News
globenewswire.com Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), a biopharmaceutical company that has developed conditionally activated…
globenewswire.com GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS…
gurufocus.com Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer Johnson and Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerPR NewswireNEW BRUNSW
globenewswire.com Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
globenewswire.com MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies,…
newsfilecorp.com Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)…
businesswire.com Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered…
globenewswire.com BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage…
globenewswire.com Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer…
globenewswire.com IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ and CD8+/IDO+ ratios in both tumor and stroma
globenewswire.com Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival…
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
benzinga.com SITE Centers Q3 FFO $(0.06) Beats $(0.09) Estimate, Sales $4.597M Miss $5.700M Estimate SITE Centers (NYSE:SITC) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 154.55 percent decrease over earnings of $0.11…
benzinga.com SITE Centers Sells Stake In 10-Property Shopping Center Portfolio Valued At $644M To Pine Tree Pine Tree, a national owner and operator of open-air shopping centers, announced that it has acquired sponsor interest in a 10-property portfolio recently appraised at $644 million and totaling 3.5…
benzinga.com Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Alcoa shares rose after Q3 earnings beat estimates; Rubico and others surged, while Nuburu, Jaguar Health and other stocks fell premarket.
benzinga.com SITE Centers (SITC) Stock Jumps 19% After Hours: What’s Driving the Surge? SITE Centers shares jump 18.94% premarket after announcing a $3 special cash distribution and plans to delist from the NYSE.
benzinga.com SITE Centers Reveals Plan to De-list From NYSE; Co. Expects De-listing Before December 4, 2026 SITE Centers Corp. (NYSE:SITC) today announced its intention to provide notice to the New York Stock Exchange of its plan to voluntarily de-list its common shares. The announcement was made in…
benzinga.com SITE Centers Announces The Sale Of Its Interests In The Dividend Trust Portfolio Joint Venture For Net Proceeds Of ~$32.4M SITE Centers Corp. (NYSE:SITC) today announced the sale of its interests in the Dividend Trust Portfolio joint venture for net proceeds of approximately $32.4 million.The Company’s Board of Directors…